Critical SP500 Stock Alerts: Citigroup, EMC, AbbVie, Mondelez International, U.S. Bancorp, and KeyCorp



Insiderslab.com has issued insider trading reports and equity research for the following companies: Citigroup (NYSE:C), EMC (NYSE:EMC), AbbVie (NYSE:ABBV), Mondelez International (NASDAQ:MDLZ), U.S. Bancorp (NYSE:USB), and KeyCorp (NYSE:KEY).
 
(Read full report by clicking the link below, you may need to copy and paste the full link to your browser.)
 
Report Highlights:
 
Citigroup Inc. (NYSE:C): Earlier this month, Citigroup Inc. (NYSE:C) announced the appointment of Jamie Forese and Manuel Medina-Mora as Co-Presidents. Moreover, Jim Cowles has been named as Chief Executive Officer of Citi’s Europe, Middle East and Africa region. What’s more, Hamid Biglari, the Head of emerging markets, is leaving the bank, Chief Executive Michael Corbat announced on Monday. Investors may want to find out how Citigroup insiders are thinking about the future of the company. Check this insider trade report for C here.
 
Read Full Report: http://www.insiderslab.com/PR3/011713A/C/Citigroup.pdf
 
EMC Corporation (NYSE:EMC): In the last three months, EMC Corporation (NYSE:EMC) insiders have totally sold US$20.44 million worth of stock, which ranged in price from US$24.69 to US$25.15 each, according to insider trading report. On January 16, the company announced significant hardware and software updates to its market-leading EMC VMAX Family. The EMC VMAX 10K, the entry product to the VMAX Family, is the current’s highest-performing of its class in the industry-and is up to twice more powerful than its predecessor. See insider trade report for EMC here.
 
Read Full Report: http://www.insiderslab.com/PR3/011713A/EMC/EMC.pdf
 
AbbVie Inc. (NYSE:ABBV): AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company formed in 2013 following separation from Abbott. Earlier this month, AbbVie’s Board of Directors declared its first quarterly cash dividend of US$0.40 per share, payable on February 15, 2013 to stockholders of record on January 15, 2013. The company will post its financial results for fourth quarter and full year 2012 on Wednesday, January 23. Check this insider trade report for ABBV here.
 
Read Full Report: http://www.insiderslab.com/PR3/011713A/ABBV/AbbVie.pdf
 
Today Insiderslab.com also observed abnormal trade volume for the following companies; insiders may involve trading in these companies. It will take some time for insiders to report their trades. Read these reports and add these companies into your Insider Trade Radar.
 
Mondelez International Inc. (NASDAQ:MDLZ):
Read Full Report: http://www.insiderslab.com/PR3/011713A/MDLZ/MondelezInternational.pdf
 
U.S. Bancorp (NYSE:USB):
Read Full Report: http://www.insiderslab.com/PR3/011713A/USB/USBancorp.pdf
 
KeyCorp (NYSE:KEY):
Read Full Report: http://www.insiderslab.com/PR3/011713A/KEY/KeyCorp.pdf
 
Insider Filing Source Reference: All observations, analysis and reports are based on public information released by the U.S. Securities and Exchange Commission.
 
About Insiderslab.com:
 
Insiderslab.com covers insider trade data in major stock markets in the U.S., Hong Kong, Mainland China, and Singapore.  Insiderslab.com features a team of experienced data analysts striving to provide the investment community with the tools, software, and data necessary to carry out more effective investment research.
 
Important Disclaimer:
Please visit insiderslab.com/disclaimers/disclaimers.php for details.
 
CONTACT: Insiders.hk, Insiderslab.com, info@insiderslab.com, Support@insiders.hk
SOURCE Insiderslab.com; Insiders.hk
Editor: Janet Nan Jiang
 
 
Source:
insiderslab.com
www.insiderslab.com

Reported on Jan 17, 2013

 
More Insider News ...

Today's Notable Trades


Alkermes plc. (ALKS)
Senior Officer (SVP, COO & CRO, Alkermes, Inc.): Pugh Gordon G

Acquired 13,750 Ordinary Shares (Non-Derivative security at $16.550) on Jul 1, 2015. Direct holding 27,860 shares/units after transaction. Holdings increased 97.45%.
Filing date: Jul 2, 2015. Record updated at 22:49:49.
 
KCG Holdings, Inc. (KCG)
Senior Officer (CEO of KCG Europe Limited): Allison Philip

Sold 117,406 Class A Common Stock, par value $0.01 per share (Non-Derivative security at $12.420) on Jul 1, 2015. Direct holding 132,594 shares/units after transaction. Holdings decreased -46.96%.
Filing date: Jul 2, 2015. Record updated at 22:49:28.
 
Juno Therapeutics, Inc. (JUNO)
10% shareholder: BRATTON DOUGLAS K

Sold 40,000 Common Stock (Non-Derivative security at $54.750) on Jul 2, 2015. Indirect holding 182,669 shares/units after transaction. Holdings decreased -17.96%.
Filing date: Jul 2, 2015. Record updated at 22:49:07.
 
ISIS PHARMACEUTICALS INC (ISIS)
First-Class Insider (Chairman and CEO): CROOKE STANLEY T

Acquired 5,000 Common Stock (Non-Derivative security at $11.270) on Jul 1, 2015. Direct holding 19,642 shares/units after transaction. Holdings increased 34.15%.
Filing date: Jul 2, 2015. Record updated at 22:47:51.
 
CAPELLA EDUCATION CO (CPLA)
Director: SHANK STEPHEN G

Sold 23,300 Common stock (Non-Derivative security at $54.114) on Jul 1, 2015. Indirect holding 83,550 shares/units after transaction. Holdings decreased -21.81%.
Filing date: Jul 2, 2015. Record updated at 22:45:00.
 
TWENTY-FIRST CENTURY FOX, INC. (FOX)
Director: DINH VIET D

Sold 3,031 Class A Common Stock (Non-Derivative security at $32.600) on Jul 1, 2015. Direct holding 0 shares/units after transaction. Holdings decreased -100.00%.
Filing date: Jul 2, 2015. Record updated at 22:44:53.
 
General Finance CORP (GFN)
Director: TASHJIAN LARRY D

Acquired 6,145 Common Stock (Non-Derivative security at $5.030) on Jul 2, 2015. Indirect holding 187 shares/units after transaction. Holdings increased 103.14%.
Filing date: Jul 2, 2015. Record updated at 22:43:22.
 
REVA Medical, Inc. (RVA:AX)
Senior Officer (VP, Scientific Affairs): Zeltinger Joan K.

Acquired 10,000 Common Stock (Non-Derivative security at $1.250) on Jul 1, 2015. Direct holding 70,000 shares/units after transaction. Holdings increased 16.67%.
Filing date: Jul 2, 2015. Record updated at 22:42:49.
 
UNITED THERAPEUTICS Corp (UTHR)
First-Class Insider (Chairman & Co-CEO): ROTHBLATT MARTINE A

Acquired 2,211 Common Stock (Non-Derivative security at $63.220) on Jul 1, 2015. Direct holding 2,451 shares/units after transaction. Holdings increased 921.25%.
Filing date: Jul 2, 2015. Record updated at 22:41:13.
 
AECOM (ACM)
Director: Dionisio John M

Sold 10,000 Common Stock (Non-Derivative security at $33.210) on Jul 1, 2015. Indirect holding 74,948 shares/units after transaction. Holdings decreased -11.77%.
Filing date: Jul 2, 2015. Record updated at 22:40:17.
 
Read more

Disclaimer

InsidersLab.com focuses on tracking and monitoring insider trading activities in the US stocks market. "Insider Trading" means trading activities created by company directors, senior officers, individual substantial shareholders, and institutional shareholders. InsidersLab.com does not represent, warrant, nor endorse the accuracy, reliability, completeness or timeliness of any of the information, content, views, opinions, recommendations or advertisements (collectively, the "Materials") contained on, distributed through, or linked, downloaded or accessed from any of the services contained on the website (the "Service"), nor the quality of any products, information or other materials displayed, purchased, or obtained by you as a result of an advertisement or any other information or offer in or in connection with the Service (the "Products"). InsidersLab.com collects insider trading information from different public sources such as newspapers, financial information websites, and government statistics publications. You hereby acknowledge that any reliance upon any Materials shall be at your sole risk. In particular, none of the Materials is provided on the InsidersLab.com website or emails with a view to inviting, inducing or encouraging any person to make any kind of investment decision. Securities or other investments referred to in the Materials may not be suitable for you and you should not make any kind of investment decision in relation to them without first obtaining independent investment advice from a person authorized to give it.